Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02089685
Brief Title: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

First Submitted : March 14, 2014
First Submitted that Met QC Criteria : March 14, 2014
First Posted : March 18, 2014 (Estimate)

Last Update Submitted that Met QC Criteria : February 15, 2021
Last Update Posted : February 16, 2021